&quot;Kevin Riggs, an instructor in medicine at Johns Hopkins University who co-authored an article about generic insulin earlier this year, doesn&#x27;t think that Open Insulin will be enough to bring a generic insulin drug to the market:<p>“I don&#x27;t think the major hurdle is that the companies don&#x27;t know how to make insulin, because that part is reasonably straightforward,” he says. “The real hurdles are getting the drug approved by the FDA (and since insulin is a biologic drug, it requires a lot more original data than an application for a small-molecule generic would), and then upfront manufacturing costs (because making a biologic drug is different, so it requires different equipment).” &quot;